CITIUS ONCOLOGY INC (CTOR)
KYG8708L1041 - Common Stock
CITIUS ONCOLOGY INC
NASDAQ:CTOR (1/8/2025, 8:00:00 PM)
After market: 1.19 +0.01 (+0.85%)1.18
-0.18 (-13.24%)
CTOR News
3 days ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq:...
4 days ago - Citius Oncology, Inc.Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
11 days ago - Yahoo FinanceAmerican Air upgraded, Nordstrom downgraded: Wall Street's top analyst callsAmerican Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls
14 days ago - Citius Oncology, Inc.Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and...
a month ago - AB Newswire“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch”2 months ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR),...
CTOR Twits
Here you can normally see the latest stock twits on CTOR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
